These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

80 related items for PubMed ID: 7895599

  • 1. Stereoselective pharmacokinetics of L-buthionine SR-sulfoximine in patients with cancer.
    Lacreta FP, Brennan JM, Hamilton TC, Ozols RF, O'Dwyer PJ.
    Drug Metab Dispos; 1994; 22(6):835-42. PubMed ID: 7895599
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice.
    Smith AC, Liao JT, Page JG, Wientjes MG, Grieshaber CK.
    Cancer Res; 1989 Oct 01; 49(19):5385-91. PubMed ID: 2766304
    [Abstract] [Full Text] [Related]

  • 3. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.
    O'Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T, Brennan J, Bookman MA, Hoffman J, Young RC, Comis RL, Ozols RF.
    J Clin Oncol; 1996 Jan 01; 14(1):249-56. PubMed ID: 8558205
    [Abstract] [Full Text] [Related]

  • 4. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.
    Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M, Spriggs DR.
    J Clin Oncol; 1994 Jan 01; 12(1):194-205. PubMed ID: 8270977
    [Abstract] [Full Text] [Related]

  • 5. Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO.
    Gallo JM, Brennan J, Hamilton TC, Halbherr T, Laub PB, Ozols RF, O'Dwyer PJ.
    Cancer Res; 1995 Oct 15; 55(20):4507-11. PubMed ID: 7553617
    [Abstract] [Full Text] [Related]

  • 6. Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment.
    Yao K, Godwin AK, Ozols RF, Hamilton TC, O'Dwyer PJ.
    Cancer Res; 1993 Aug 15; 53(16):3662-6. PubMed ID: 8101766
    [Abstract] [Full Text] [Related]

  • 7. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
    Vanhoefer U, Cao S, Minderman H, Toth K, Skenderis BS, Slovak ML, Rustum YM.
    Clin Cancer Res; 1996 Dec 15; 2(12):1961-8. PubMed ID: 9816155
    [Abstract] [Full Text] [Related]

  • 8. L-Buthionine (S,R) sulfoximine depletes hepatic glutathione but protects against ethanol-induced liver injury.
    Donohue TM, Curry-McCoy TV, Todero SL, White RL, Kharbanda KK, Nanji AA, Osna NA.
    Alcohol Clin Exp Res; 2007 Jun 15; 31(6):1053-60. PubMed ID: 17428293
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of trimetrexate administered by five-day continuous infusion to patients with advanced cancer.
    Reece PA, Morris RG, Bishop JF, Olver IN, Raghavan D.
    Cancer Res; 1987 Jun 01; 47(11):2996-9. PubMed ID: 2952262
    [Abstract] [Full Text] [Related]

  • 10. The effect of L-buthionine-[S,R]-sulfoximine on the pancreas in mice. A model of weakening glutathione-based defense mechanisms.
    Lüthen RE, Neuschwander-Tetri BA, Niederau C, Ferrell LD, Grendell JH.
    Int J Pancreatol; 1994 Aug 01; 16(1):31-6. PubMed ID: 7528760
    [Abstract] [Full Text] [Related]

  • 11. Stereospecific pharmacokinetics of rac-5-methyltetrahydrofolic acid in patients with advanced colorectal cancer.
    Mader RM, Steger GG, Rizovski B, Djavanmard MP, Scheithauer W, Jakesz R, Rainer H.
    Br J Clin Pharmacol; 1995 Sep 01; 40(3):209-15. PubMed ID: 8527281
    [Abstract] [Full Text] [Related]

  • 12. Buthionine sulfoximine induction of gamma-L-glutamyl-L-cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicity in human glioma cells.
    Ali-Osman F, Antoun G, Wang H, Rajagopal S, Gagucas E.
    Mol Pharmacol; 1996 Jun 01; 49(6):1012-20. PubMed ID: 8649339
    [Abstract] [Full Text] [Related]

  • 13. Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity.
    Liebmann JE, Hahn SM, Cook JA, Lipschultz C, Mitchell JB, Kaufman DC.
    Cancer Res; 1993 May 01; 53(9):2066-70. PubMed ID: 8097674
    [Abstract] [Full Text] [Related]

  • 14. Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients.
    Cerqueira PM, Cesarino EJ, Mateus FH, Mere Y, Santos SR, Lanchote VL.
    Chirality; 1999 May 01; 11(7):591-7. PubMed ID: 10423287
    [Abstract] [Full Text] [Related]

  • 15. Rate of buthionine sulfoximine entry into brain and xenotransplanted human gliomas.
    Fekete I, Griffith OW, Schlageter KE, Bigner DD, Friedman HS, Groothuis DR.
    Cancer Res; 1990 Feb 15; 50(4):1251-6. PubMed ID: 2297773
    [Abstract] [Full Text] [Related]

  • 16. Cytotoxic effects of glutathione synthesis inhibition by L-buthionine-(SR)-sulfoximine on human and murine tumor cells.
    Dorr RT, Liddil JD, Soble MJ.
    Invest New Drugs; 1986 Feb 15; 4(4):305-13. PubMed ID: 3583642
    [Abstract] [Full Text] [Related]

  • 17. Lack of enhanced myelotoxicity with buthionine sulfoximine and sulfhydryl-dependent anticancer agents in mice.
    Soble MJ, Dorr RT.
    Res Commun Chem Pathol Pharmacol; 1987 Feb 15; 55(2):161-80. PubMed ID: 3823607
    [Abstract] [Full Text] [Related]

  • 18. Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans.
    Le Corre P, Gibassier D, Sado P, Le Verge R.
    Drug Metab Dispos; 1988 Feb 15; 16(6):858-64. PubMed ID: 2907466
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
    Welink J, Boven E, Vermorken JB, Gall HE, van der Vijgh WJ.
    Clin Cancer Res; 1999 Sep 15; 5(9):2349-58. PubMed ID: 10499604
    [Abstract] [Full Text] [Related]

  • 20. Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan.
    Bailey HH, Ripple G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Mahvi D, Schink J, Pomplun M, Mulcahy RT, Wilding G.
    J Natl Cancer Inst; 1997 Dec 03; 89(23):1789-96. PubMed ID: 9392620
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.